WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Stock Ownership - Who owns Protagonist Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Protagonist Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Arturo Md MolinaChief Medical Officer2026-01-209,514$82.48
$784.71kSell
Asif AliChief Financial Officer2026-01-208,588$82.48
$708.34kSell
Dinesh V. Ph D. PatelPresident and CEO2026-01-2034,438$82.48
$2.84MSell
Harold E. SelickDirector2026-01-0914,299$4.21
$60.20kBuy
Arturo Md MolinaChief Medical Officer2025-11-172,712$84.77
$229.90kSell
William D. WaddillDirector2025-10-108,000$87.81
$702.48kSell
William D. WaddillDirector2025-10-104,000$69.25
$277.00kSell
William D. WaddillDirector2025-10-1012,000$6.98
$83.76kBuy
William D. WaddillDirector2025-09-224,000$64.25
$257.00kSell
William D. WaddillDirector2025-08-274,000$59.25
$237.00kSell

1 of 3

PTGX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PTGX insiders and whales buy or sell their stock.

PTGX Shareholders

What type of owners hold Protagonist Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc15.04%9,404,232$773.97MInstitution
Farallon Capital Management LLC9.91%6,196,006$509.93MInstitution
Rtw Investments LP9.21%5,756,277$473.74MInstitution
Vanguard Group Inc6.81%4,257,229$350.37MInstitution
State Street Corp5.06%3,165,795$260.54MInstitution
Bvf Inc4.10%2,560,916$210.76MInstitution
Julie Papanek3.92%2,453,255$201.90MInsider
Johnson Johnson3.92%2,449,183$201.57MInstitution
Johnson Johnson3.92%2,449,183$201.57MInsider
Canaan X LP3.39%2,116,552$174.19MInsider

1 of 3

PTGX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PTGX82.80%17.20%Net SellingNet Selling
KYMR75.15%24.85%Net BuyingNet Buying
CRSP67.81%32.19%Net BuyingNet Selling
MIRM52.20%47.80%Net BuyingNet Buying
BLTE7.19%0.00%
View Top Biotech Stocks

Protagonist Therapeutics Stock Ownership FAQ

Who owns Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ: PTGX) is owned by 113.06% institutional shareholders, 23.49% Protagonist Therapeutics insiders, and 0.00% retail investors. Julie Papanek is the largest individual Protagonist Therapeutics shareholder, owning 2.45M shares representing 3.92% of the company. Julie Papanek's Protagonist Therapeutics shares are currently valued at $203.82M.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.